Abstract
Despite newer agents, chemotherapy-induced nausea and vomiting (CINV) continues to remain a distressing side effect to a proportion of patients undergoing systemic anti-cancer therapy. We recently performed an unplanned secondary analysis on a previously reported negative phase III trial (N08C3) looking at the efficacy of gabapentin/placebo in combination with dexamethasone and a 5HT3 receptor antagonist in the prevention of CINV for 413 patients undergoing regimens with highly emetogenic chemotherapy (HEC). In the current study, we attempted to better understand the higher than expected rate of overall patient satisfaction, despite a low complete response rate in both arms. Additionally, we looked at patient variables and their relationship to rates of CINV. Approximately one third of patients experienced more than mild nausea and reported scores on the Functional Living Index-Emesis that indicated interference with activities. Thirty-five percent reported nausea greater than 2.5 on a scale of 0 to 10 (0 being none), 19 % reported at least one emetic episode, and 49 % reported taking rescue medication. Nausea and vomiting on day 1, cisplatin therapy, and history of motion sickness significantly predicted delayed CINV. Age, com...Continue Reading
References
Oct 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M G KrisD P Kelsen
Jan 23, 1999·The New England Journal of Medicine·R M NavariB J Gertz
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J HeskethS L Silberman
Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D CamposB J Gertz
May 13, 2004·Cancer·Steven M GrunbergGedske Daugaard
Jun 9, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·David G WarrKevin J Horgan
Sep 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brigitte Bloechl-DaumJørn Herrstedt
Nov 15, 2006·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Lorenzo CohenHenry Hu
Sep 1, 2004·Journal of the National Comprehensive Cancer Network : JNCCN·Joseph A RoscoeAbhay R Shelke
Jun 10, 2010·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Amin HaideraliJessica Wegner
Jan 25, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Doranne L HilariusNeil K Aaronson
Mar 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven GrunbergJørn Herrstedt
Aug 23, 2012·Journal of the National Cancer Institute·Lucas Vieira dos SantosJoão Paulo da Silveira Nogueira Lima
Jan 10, 2013·Current Oncology·N BouganimM Clemons
Mar 21, 2013·Current Oncology Reports·Morgan TrammelHoward McLeod
Jul 22, 2014·Cancer·Debra L BartonCharles L Loprinzi
Sep 18, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Lee Schwartzberg
Mar 22, 2015·The Oncologist·Matti AaproDavid Warr
Citations
Sep 2, 2016·Therapeutic Advances in Medical Oncology·Omar Abdel-Rahman
Feb 15, 2017·Frontiers in Pharmacology·Bernardo L Rapoport
Oct 12, 2018·International Journal of Molecular Sciences·Gan QiaoXiukun Lin
Jul 8, 2020·Toxins·Qinghua WuWenda Wu
Nov 2, 2019·Molecular Biology Reports·Shuai WenShili Sun
Dec 29, 2020·Cancer Treatment and Research Communications·Kush GuptaS P Kataria
Feb 14, 2021·Toxicology·Qinghua WuKamil Kuca
Mar 2, 2021·Journal of Geriatric Oncology·Koung Jin SuhJee Hyun Kim
Jul 30, 2021·European Journal of Cancer Care·Elise J DevlinJoseph Roscoe
Sep 22, 2020·Complementary Therapies in Medicine·Jing-Yu TanTao Wang
Nov 24, 2021·Asia-Pacific Journal of Clinical Oncology·Mastura Md YusofMohd Haris Fadzillah Bin Abdul Rahman